CLINICAL QUESTION
Are selective serotonin reuptake inhibitors (SSRIs) safe and effective for the management of symptoms in patients with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD)?
EVIDENCE-BASED ANSWER
SSRIs likely reduce overall symptom severity in patients with PMS or PMDD compared with placebo.1 Continuous dosing may be more effective than luteal phase dosing, although both may reduce patient rating of symptoms. Adverse effects associated with SSRI use include nausea, insomnia, decreased energy, and sexual dysfunction. (Strength of Recommendation: B, inconsistent or limited-quality patient-oriented evidence.)
PRACTICE POINTERS
Premenstrual disorders, which include PMS and PMDD, occur during the luteal phase of the menstrual cycle.1,2 PMS affects many menstruating patients and can result in marked functional impairment. Up to 6% of women meet criteria for PMDD, a more severe form of PMS that is characterized by significant mood lability, irritability, or depressed mood.2 Authors of this Cochrane review sought to evaluate the effectiveness and safety of SSRIs in the management of PMS and PMDD.
This Cochrane review included 34 randomized controlled trials with 4,563 patients ages 18 to 49 years with a diagnosis of severe PMS or PMDD (more significant psychological symptoms and longer symptom duration than PMS).1 The SSRIs fluoxetine, paroxetine, sertraline, escitalopram, and citalopram in varying doses were compared with placebo. Primary outcome was overall self-rated premenstrual symptoms (eg, depression, anxiety, irritability); secondary outcomes included response rate, adverse events, and specific symptoms of PMS or PMDD. Validated symptom scales, including daily symptom diaries and standardized premenstrual symptom scales, were used across trials. Trial duration varied but typically ranged from two to six menstrual cycles. The review evaluated the 12 most common and serious SSRI-associated adverse events (ie, nausea, insomnia, sexual dysfunction, fatigue, presyncope or vertigo, tremor, somnolence, diaphoresis, xerostomia, asthenia, diarrhea, and constipation). Most trials were conducted in high-income settings, and approximately 68% of the studies were funded by pharmaceutical companies.
SSRIs moderately improved self-rated global premenstrual symptoms compared with placebo across dosing groups (standardized mean difference [SMD] = −0.57; 95% CI, −0.72 to −0.42; 12 studies; n = 1,742; moderate-certainty evidence).1 When dosing strategy was examined, luteal phase (typically the 14 days before menses) and continuous daily regimens were more effective than placebo, but continuous dosing was associated with a larger effect size than luteal phase dosing (SMD = −0.69 vs −0.39; P = .03 for subgroup difference). The review did not include head-to-head comparisons among individual SSRIs, suggesting that the choice of SSRI may be guided by previous patient experience with and response to SSRIs, drug interactions, and patient preference.
Adverse effects were more common with SSRIs than placebo.1 Common SSRI-associated adverse events included nausea (number needed to harm [NNH] = 7); asthenia (NNH = 10); somnolence (NNH = 16); dry mouth (NNH = 16); insomnia (NNH = 20); and sexual dysfunction (NNH = 25).
The overall certainty of evidence was rated moderate because of incomplete reporting of randomization and allocation methods, suspected publication bias, and substantial pharmaceutical sponsorship.1
The American College of Obstetricians and Gynecologists practice guidelines recommend SSRIs as first-line pharmacotherapy for the management of affective premenstrual symptoms.3 The SSRIs currently approved by the US Food and Drug Administration for treatment of PMDD are fluoxetine, sertraline, and paroxetine. Before initiating pharmacotherapy, clinicians should engage in shared decision-making that incorporates patient preferences, reproductive plans, coexisting mood disorders, and adverse effects.
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
